Beth Hecht, See Remarks at Xeris Biopharma Holdings, Inc. (XERS), sold 202,889 shares at $7.45 ($1.5M) on 2026-02-02, disclosed to the SEC on 2026-02-02.
Seasonal sale ($1.5M) by See Remarks — this insider has traded XERS in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.36 | 24,266 | $179K | 11.9% |
| 2 | $7.36 | 46,914 | $345K | 23.1% |
| 3 | $7.36 | 98,375 | $724K | 48.4% |
| 4 | $7.45 | 16,667 | $124K | 8.3% |
| 5 | $7.45 | 16,667 | $124K | 8.3% |
| Total | $7.37 avg | 202,889 |
| $1.5M |
| 100% |
| Filing → |
| XERS | SELL | 2026-07-02 | $134K | — | Filing → |
| XERS | SELL | 2026-06-02 | $101K | — | Filing → |
| XERS | SELL | 2026-05-01 | $104K | — | Filing → |